IFNG and myeloproliferative neoplasm: We found that ruxolitinib and dBET6 completely suppress IFN‐γ‐induced expression of PD‐L1 in phenotypically defined (CD34+CD45dimCD38−) MPN NSC, while JQ1 did not show a significant effect (Figure 3F).